We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 12 investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
The first wholesaler to offer insurance products for B2B and B2C firms in the Sharing Economy. Inlet aims provide insurance for assets that have been peer-to-peer rented for the short term, or for the provision of services such as letting properties online, as these markets are not currently covered by traditional insurances. Inlet generates revenue from commissions via insurance products at the point of sale and at policy renewal. Income in the form of interest payments is also earned from customers that choose to pay via direct debit on a monthly basis, as well as from fees applied to customers who wish to amend their policies.
days to go: Expired investment: £256,514
MyFirstUK is a car insurance platform for first time driver. It aims to offer young people the perfect cover at the right price and also provide them with all of the guidance they need to make an informed decision. 
days to go: Expired investment: £61,920
Nimbli is a London-based Fintech company which is promoting financial inclusion in East Africa by using innovative technology. It is currently working in strategic partnership with a Major African Bank to launch its mobile application in 1Q 2019. Through its mobile application, Nimbli will provide better financial services to small and medium enterprises (SMEs) and help in reducing the number of people who don’t have credit access to zero.  
days to go: Expired investment: £65,670
Lenderwize are a SEIS approved, UK based Crowdlending platform for Telcos. They seek to bridge the cash flow gap for telecom operators which sell to big operators and must pay their vendors upfront whilst waiting for their own clients to pay them. Lenderwize currently has a working platform with over £5,000,000 in requests from borrowers and over £9,000,000 from institutional investors.  
days to go: Expired investment: £78,076
Ablrate.com is an FCA regulated peer to peer lending platform which connects lenders with borrowers for asset-backed loans. It was launched in late 2014 and has a community of 5000 lenders who have completed £1 million+ worth of loans per month to all sizes of businesses throughout the UK.
days to go: Expired investment: £457,950
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph